LINC 2017 Highlights
Boston Scientific leads the Drug-Eluting Technology debate at LINC 2017
Boston Scientific’s drug-eluting technology was among the highlights at the Leipzig Interventional Course in Germany in January, when more than 5,000 physicians from over 75 countries met to learn how technological advancements are contributing to improving daily clinical practice.
The LINC program included discussions on drug-eluting solutions through several lectures and thought-provoking debates about novel endovascular techniques, including thrombectomy and venous disease.
Drug-eluting technology in Europe: what perspectives?
Professor Scheinert pointed out that drug-eluting technology today has become the treatment of choice for fempop lesions in claudicants, compared with the reservations about this technology that physicians had only a few years ago. However, adoption in Europe is lagging for a number of reasons, mainly due to the low level or even the absence of reimbursement from payers.
Still, the panel remained upbeat about the improving prospects for DET in Europe in the next few years as economic considerations start to shift toward the broader picture of lower reintervention rates, instead of focusing on the cost of the single procedure.
A bold clinical program
The symposium provided Boston Scientific with the opportunity to showcase its bold clinical program . Boston Scientific is currently the only medical device company who offers both drug-eluting stents and drug-coated balloons, providing physicians with a choice of treatments that can be adapted based on the patient’s needs.
The choice between drug-eluting balloons and drug-eluting stents varies depending on a number of factors such as the patient, the type of lesion, the presence of co-morbidity (s), as well as economic implications. Clinical data and head-to-head comparisons can offer a framework for physicians, but when it comes to choosing the best treatment option for a particular patient, there is no one-size-fits-all approach. Further trials and more real-world data will help to better define treatment algorithms in the future.
Is there a future for drug-eluting technology in BTK?
The LINC program also included several sessions on the future of drug-eluting technologies in below-the-knee (BTK) treatment. Professor Francesco Liistro (San Donato Hospital, Arezzo, Italy) provided promising insights in his presentation of preliminary data from a single-center study in Italy comparing drug-coated balloons with plain old balloon angioplasty in patients with critical limb ischemia. Although POBA is still considered the method of choice for below-the-knee artery disease, its high rates of restenosis and reintervention make it far from ideal. Professor Liistro noted that preliminary data show drug-eluting balloons could reduce restenosis and the reocclusion of the vessel.
More clinical data is needed to drive a definitive conclusion, but the presentation demonstrated that the interest in drug-coated balloons for the treatment of below-the-knee arterial disease is high within the medical community.
A “great debate” on venous interventions
WANT TO KNOW MORE?
Join our Drug-Eluting Technologies Community
Sign Up for Product Updates
Receive the latest news of Drug Eluting TechnologiesSIGN UP